Michael David  Smith net worth and biography

Michael Smith Biography and Net Worth

Michael joined KalVista in February 2016 as Vice President of Clinical Development before being promoted to Senior Vice President of Development. Michael has nearly 20 years of development experience in the pharmaceutical industry. Recent experience includes senior management positions with Global Scientific Affairs, Early Development in the United States and Europe as well as Clinical Development and Regulatory Affairs at a US-based specialty pharma.

Michael received a PharmD from the University of Utah and a BS in Neuroscience from Brigham Young University. He maintains an appointment as Adjunct Assistant Professor, College of Pharmacy, University of Utah.

What is Michael David Smith's net worth?

The estimated net worth of Michael David Smith is at least $119,166.60 as of April 28th, 2021. Dr. Smith owns 10,014 shares of KalVista Pharmaceuticals stock worth more than $119,167 as of March 28th. This net worth approximation does not reflect any other assets that Dr. Smith may own. Learn More about Michael David Smith's net worth.

How old is Michael David Smith?

Dr. Smith is currently 44 years old. There are 6 older executives and no younger executives at KalVista Pharmaceuticals. The oldest executive at KalVista Pharmaceuticals is Dr. Edward P. Feener Ph.D., Chief Scientific Officer, who is 64 years old. Learn More on Michael David Smith's age.

How do I contact Michael David Smith?

The corporate mailing address for Dr. Smith and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Michael David Smith's contact information.

Has Michael David Smith been buying or selling shares of KalVista Pharmaceuticals?

Michael David Smith has not been actively trading shares of KalVista Pharmaceuticals during the last ninety days. Most recently, Michael David Smith sold 10,014 shares of the business's stock in a transaction on Wednesday, April 28th. The shares were sold at an average price of $25.76, for a transaction totalling $257,960.64. Following the completion of the sale, the vice president now directly owns 10,014 shares of the company's stock, valued at $257,960.64. Learn More on Michael David Smith's trading history.

Who are KalVista Pharmaceuticals' active insiders?

KalVista Pharmaceuticals' insider roster includes Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Michael Smith (VP), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.

Are insiders buying or selling shares of KalVista Pharmaceuticals?

During the last year, KalVista Pharmaceuticals insiders bought shares 13 times. They purchased a total of 448,522 shares worth more than $5,806,280.30. During the last year, insiders at the specialty pharmaceutical company sold shares 13 times. They sold a total of 212,109 shares worth more than $2,650,351.15. The most recent insider tranaction occured on February, 20th when insider Edward P Feener sold 28,288 shares worth more than $398,012.16. Insiders at KalVista Pharmaceuticals own 12.3% of the company. Learn More about insider trades at KalVista Pharmaceuticals.

Information on this page was last updated on 2/20/2024.

Michael David Smith Insider Trading History at KalVista Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/28/2021Sell10,014$25.76$257,960.6410,014View SEC Filing Icon  
See Full Table

Michael David Smith Buying and Selling Activity at KalVista Pharmaceuticals

This chart shows Michael David Smith's buying and selling at KalVista Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $11.90
Low: $10.92
High: $12.46

50 Day Range

MA: $13.57
Low: $11.07
High: $16.04

2 Week Range

Now: $11.90
Low: $6.83
High: $16.88

Volume

1,847,301 shs

Average Volume

810,012 shs

Market Capitalization

$502.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9